NCT04417699View on ClinicalTrials.gov

SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

December 14, 2023

Study Completion Date

February 21, 2024

Conditions
Rectal Cancer
Interventions
DRUG

TAS 102

Oral medication over Days 1-5

DRUG

Oxaliplatin

Administered by intravenous infusion over 2 hours on day 1

Trial Locations (4)

10032

Columbia University Irving Medical Center/NYPH, New York

92868

University of California, Irvine, Orange

97213

Providence Portland Medical Center, Portland

98101

Virginia Mason Medical Center, Seattle

Sponsors

Collaborators (1)

Taiho Oncology
All Listed Sponsors
collaborator

Taiho Oncology

UNKNOWN

lead

Providence Health & Services

OTHER